Establishing Treatment Standards through Comparative Effectiveness Research by Ratner, MD, FACE, Robert E.
Robert E. Ratner, MD
Senior Scientist, Medstar Research Institute
Professor of Medicine, Georgetown University
Robert Wood Johnson Health Policy Fellow
Study Director, Institute Of Medicine
Comparative Effectiveness Research Priorities
Establishing Treatment Standards 
through 
Comparative Effectiveness Research
Patient-Centered Health Research 
is Vital to Health Reform
In situations where the right thing to do is well established, 
physicians from high- and low-cost cities make the same 
decisions.
But in cases where the science is more unclear, some physicians 
pursue the maximum possible amount of testing and 
procedures; some pursue the minimum. 
And what kind of doctor they are depends on where they came 
from.  In case after uncertain case, more was not necessarily 
better.
(Atul Gawande, New Yorker Magazine) 
Disparate Growth In Per Capita 
Medicare Expenditures Over Time
Age-sex-race adjusted, in 2006 Dollars
Quality of Evidence in Clinical Guidelines
AHA/ACC Heart Disease Recommendations
Source: Robert Califf, IOM Meeting on Evidence-based Medicine, December 2007
Why so many “C’s”?
• The paradox
– 18,000 new randomized controlled trials published in 2007
– “Available evidence is limited or poor quality”
Are we asking the right questions?
6Patient-Provider
X
The Obvious Policy Issue
We need to generate new data on what works 
best for whom, under what circumstances.
Recovery Act’s $1.1B for 
Patient-Centered Health Research
Implementation Update:
• Federal Coordinating Council established
• Institute Of Medicine (IOM) Report commissioned
• Reports from IOM & Council delivered June 30, 2009
• FY09 spending plans to Congress July 30, 2009
• RFAs from National Institutes of Health and Agency for 
Healthcare Research and Quality announced and under review
• $200-300 million per year for 10 years in health reform

Committee’s Definition of CER
The generation and synthesis of evidence that 
compares the benefits and harms of alternative 
methods to prevent, diagnose, treat, and monitor a 
clinical condition or to improve the delivery of 
care.
The purpose of CER is to assist consumers, 
clinicians, purchasers, and policy makers to make 
informed decisions that will improve health care at 
both the individual and population levels.
Guiding Principle: 
The Value of Information (VOI)
• Definition: Difference between the value of the outcome 
given the decision one would make in the absence of 
additional information and the value of the outcome of the 
decision that would be made as additional information became 
available as a result of research 
p(A>B)
Study A vs. B
Guess A > B
p(B>A)
A if A>B
B if B>A
A Value of Research is : 
(B-A) if B>A = p(B>A) (B-A)
Inputs into VOI Calculation
• Choice to be Made: Identification of the relevant set of 
alternatives to be compared
• Value of Outcomes: Construction of an outcome measure to 
compare benefits across interventions 
• Potential Findings of Research: Characterization of how 
additional research might change uncertainty of the outcomes of 
an intervention
• Probability of Change in Choice: Prediction of the probability 
that clinical choices will change in response to research results 
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Secondary Research Area
Primary Research Area
Distribution of the recommended research priorities 
by primary and secondary research areas
• Compare the effectiveness and cost-effectiveness of 
conventional medical management of type 2 diabetes in 
adolescents and adults, versus conventional therapy plus 
intensive educational programs or programs incorporating 
support groups and educational resources.
• Compare the effectiveness of comprehensive care 
coordination programs, such as the medical home, and 
usual care in managing children and adults    with severe 
chronic disease, especially in populations with known 
health disparities.
• Compare the effectiveness of   accountable care systems and usual 
care on costs, processes of care, and outcomes for geographically 
defined populations of patients with one or more chronic diseases.
• Compare the effectiveness of different benefit design, utilization 
management, and cost-sharing strategies in improving health care 
access and quality in patients with chronic diseases (e.g., cancer, 
diabetes, heart disease).
• Compare the effectiveness (including resource utilization, 
workforce needs, net health care expenditures, and requirements 
for large-scale deployment) of new remote patient monitoring and 
management technologies (e.g., telemedicine, Internet, remote 
sensing) and usual care in managing chronic disease, especially in 
rural settings.
• Compare the effectiveness of traditional behavioral 
interventions versus economic incentives in motivating 
behavior changes (e.g., weight loss, smoking cessation, 
avoiding alcohol and substance abuse) in children and 
adults.
• Compare the effectiveness of strategies for enhancing 
patients’ adherence to medication regimens.
• Compare the effectiveness of different disease management 
strategies for activating patients with chronic disease.
• Compare the effectiveness of shared decision making and 
usual care on decision outcomes (treatment choice, 
knowledge, treatment-preference concordance, and decisional 
conflict) in children and adults with chronic disease such as 
stable angina and asthma.
• Compare the effectiveness of patient decision support tools 
on informing diagnostic and treatment decisions (e.g., 
treatment choice, knowledge acquisition, treatment-
preference concordance, decisional conflict) for elective 
surgical and nonsurgical procedures—especially in patients 
with limited English-language proficiency, limited education, 
hearing or visual impairments, or mental health problems.
• Compare the effectiveness of strategies for enhancing patients’
adherence to medication regimens.
• Compare the effectiveness of different disease management 
strategies for activating patients with chronic disease.
• Compare the effectiveness of alternative redesign strategies—
using decision support capabilities, electronic health records, 
and personal health records—for increasing health 
professionals’ compliance with evidence-based guidelines and 
patients’ adherence to guideline-based regimens for chronic 
disease care.
• Compare the effectiveness of various strategies (e.g., 
clinical interventions, selected social interventions [such as 
improving the built environment in communities and 
making healthy foods more available], combined clinical 
and social interventions) to prevent obesity, hypertension, 
diabetes, and heart disease in at-risk populations such as the 
urban poor and American Indians.
• Compare the effectiveness of school-based interventions 
involving meal programs, vending machines, and physical 
education, at different levels of intensity, in preventing and 
treating overweight and obesity in children and adolescents.
• Compare the effectiveness of treatment strategies for 
obesity (e.g., bariatric surgery, behavioral  interventions, 
pharmacologic treatment) on the resolution of obesity-
related outcomes such as diabetes, hypertension, and 
musculoskeletal disorders.
• Compare the effectiveness of interventions (e.g., 
community-based multilevel interventions, simple health 
education, usual care) to reduce health disparities in 
cardiovascular disease, diabetes, cancer, musculoskeletal    
diseases, and birth outcomes.
An interactive file of the list of 
priority topics is available on the 
project website at: 
www.iom.edu/cerpriorities
Categories of CER Methods
• Systematic reviews of existing research
• Decision modeling, with or without cost information
• Retrospective analysis of existing clinical or administrative 
data
• Prospective non-experimental studies, including 
observational epidemiologic studies and registries
• Experimental studies, including randomized clinical trials 
(RCTs)
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Pragmatic Clinical Trials - Definitions
Schwartz D and Lellouch J. Explanatory and pragmatic 
attitudes in therapeutical trials. J Chron Dis 1967; 20:637-
648.
“Should one prefer the goal of immediate applicability 
with a sacrifice of true understanding, or the more distant 
goal which may lead to greater enlightenment and which 
may prove more fertile for the future?”
Pragmatic Clinical Trials
• Use a pragmatic design for the study:
– If outcome is relevant to patients 
– If outcome has little mechanistic importance
• Choose outcomes of clinical relevance including 
patient-reported outcomes and Quality of Life
• Heterogeneous populations with co-morbidities are 
desirable, regardless of the impact on withdrawal
What Are Adaptive Trials?
• Trials that change based on prospective rules and the 
accruing information:
– Adaptive sample sizes
– Adaptive randomization
– Adaptive accrual rate
– Drop/Re-enter arms or dose groups
– Combination therapies
– Stop early for success or terminate early for futility
– Adapt to responding sub-populations
– Adaptive borrowing of information
– Seamlessly combine phases of development
What Does Bayes Add to CER?
• Synthesis
– Bayes is ideal for combining information
– Meta-analysis or combining past studies with new data
• Prediction
– Uses longitudinal models within trials
– Produce predictive probabilities of trial success
– Predict individual patient result on different treatments
• Personalized Medicine
– Bayes conditions on all known data
– Combines patient-specific information and known historical data
– Probabilities average over uncertainty in historical estimates
All Methods Have a Role
• Inevitable trade-off between internal validity and 
feasibility, generalizability, cost, time
• The nature of the research question, and the decision 
maker will influence best practices
• Experimental studies will have a crucial role in CER, and 
there is need for improving design and implementation
• Non-experimental methods hold great promise, 
particularly as methods are refined and data infrastructure 
is improved
31
What is Included in
Comparative Effectiveness Research?
Evidence 
communication: 
dissemination of 
findings
Evidence 
generation: 
secondary 
analysis of 
databases
Evidence 
synthesis: 
cost-
effectiveness 
analyses
Evidence 
synthesis: 
systematic 
reviews
Evidence 
generation:
clinical trials & 
observational 
studies
Evidence 
translation: 
generation of 
clinical 
guidelines
Prioritization of gaps 
in evidence generation, 
synthesis, 
communication,         
or translation
Requires clinical input
Source:  S. West, M. Viswanathan, RTI
Spring 2009


What This Study Adds
• No randomized controlled trials of parachute use have 
been undertaken
• The basis for parachute use is purely observational, and 
its apparent efficacy could potentially be explained by a 
“healthy cohort” effect
• Individuals who insist that all interventions need to be 
validated by a randomized controlled trial need to come 
down to Earth with a bump!
